Drug intelligence / Profile preview

PHI3

Development stage: Unknown
Lead developer: PharOS
Modality: Small Molecules
Administration: Oral

Overview

PHI3 is a novel, orally active small molecule developed by Pharos iBio that functions as a dual BRAF/FLT3 kinase inhibitor. It is being investigated for the treatment of acute myeloid leukemia (AML), particularly in patients with FLT3 mutations, including those who have developed resistance to other FLT3 inhibitors due to RAS mutations. The drug aims to overcome resistance by dually targeting FLT3 and the RAS/MAPK pathway.

Targets

CHEK2 (Checkpoint kinase 2)FLT3 (Fms related receptor tyrosine kinase 3)

Beyond the preview

Go deeper on PHI3.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PHI3.

Explore the full profile